Innovative research
Our Products
Holburn is committed to our strategic vision of growth and profitability, with a focus on novel biomedical R&D programs in the healthcare diagnostic and therapeutic spheres. We conduct leading-edge studies in pathology and gastrointestinal physiology, building an intellectual property (IP) inventory.
Product pipeline
-
Holburn is formulating, testing and manufacturing cannabinoid-based tablets to act as anti-inflammatory substances, particularly for patients with irritable bowel syndrome (IBS).
-
Companion diagnostics encompasses the process of screening patients for a particular biomolecular marker, which can then be used to determine the likelihood of successful treatment with a particular therapeutic compound. This may enable clinicians to recognize patients with different types of diseases ranging from cancer to functional bowel disorders.
-
Holburn is developing novel stable reagents for histological methods, raising novel antibodies for use in research and diagnostic pathology, designing novel probes for the identification of new drug targets and generating control materials.
The future of healthcare diagnostics & therapeutics
From early diagnosis to tailored treatment, in the future of healthcare diagnostics and therapeutics, anything is possible.
Join us in shaping the future — contact us to find out how.